![]() Solutions like Tablo will help us deliver on a differentiated patient experience.”ĭesigned for total care of chronic kidney disease (CKD) and end-stage renal disease (ESRD) in a value-based setting, Strive upends the traditional model for kidney care by combining predictive analytics with high-touch, compassionate care teams. “Kidney disease patients deserve access to better, intuitive technology. We’ve set out on a mission to change that through predictive analytics, high-quality, compassionate care and partnerships with other forward-thinking technology companies,” said Chris Riopelle, CEO of Strive Health. “The current standard of care for people living with kidney disease falls short for most patients. Strive Health will use Outset’s Tablo Hemodialysis System to expand patient access to home hemodialysis. A rapidly growing organization focused on slowing kidney disease progression and preventing costly hospitalizations through a proprietary whole-patient solution. (Nasdaq: OM), a dialysis technology innovator, announced a collaboration to help further the companies’ efforts to change the kidney care paradigm. Past results do not guarantee a similar outcome. San Jose, CA – JStrive Health, the national leader in value-based kidney care, and Outset Medical, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.Īttorney Advertising. To be notified if a class action against Li-Cycle Holdings Corp. Shareholders pay no fees or expenses.Ībout Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Contact us for more information about your rights.Īll representation is on a contingency fee basis. (LICY) between Februand March 23, 2022, you have legal options. Next Steps: If you acquired shares of Li-Cycle Holdings Corp. On this news, Li-Cycle’s shares fell approximately 5.6%, to close at $7.93 per share on March 24, 2022. The truth came to light on March 24, 2022, when market researcher Blue Orca Capital released a report describing the Company as “a near fatal combination of stock promotion, laughable governance, a broker business hemorrhaging cash, and highly questionable Ernon-like accounting” and detailing the Company’s failings. With regard to accounting, the Company gave a false impression of growth, reported revenues derived by marking up receivables on unsold products, and concealed that the Company would need an additional $1 billion to support planned growth. Further, Li-Cycle engaged in questionable related party transactions. would enable Li-Cycle “to fully fund its planned global expansion.” However, defendants failed to disclose that Li-Cycle’s largest customer was merely a broker providing working capital financial to the Company while trying to sell the product to end customers. What is this Case About: According to a complaint filed against Li-Cycle, defendants touted Li-Cycle’s patented technology and noted that the merger with Peridot Acquisition Corp. If you would like more information about our investigation of Li-Cycle Holdings Corp.’s misconduct, click here. Li-Cycle purports to be an industry leader in lithium-ion battery resource recovery and the leading lithium-ion battery recycler in North America. (NYSE: LICY) and its officers and directors to determine whether they breached their fiduciary duties and violated securities laws. SAN DIEGO–(BUSINESS WIRE)– $LICY #classaction–Shareholder rights law firm Robbins LLP is investigating Li-Cycle Holdings Corp.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |